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tery disease  [7, 8] as well as an increased risk of 
myocardial infarction.
Increased levels appear to reduce the overall 
cardiovascular risks  [9]. Experimental evidence 
implies that adiponectin inhibits hypertrophic sig-
naling in the myocardium [10] and may thus in-
Adiponectin is an adipocyte-derived hormone 
and plays a role in insulin-sensitizing [1], antiath-
erogenic  [2], anti-inflammatory properties  [3, 4]. 
Reduced adiponectin levels have been reported in 
obesity (especially visceral obesity), diabetes, insu-
lin resistance, hypertension [5, 6] and coronary ar-
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Abstract
Background. Adiponectin is an adipocytes-derived hormone which has been shown to possess insulin-sensitiz-
ing, antiatherogenic, and anti-inflammatory properties. In acromegaly, the data on adiponectin is contradictory. 
The relationship between adiponectin levels and cardiac parameters has not been studied.
Objectives. The aim of this study was to find out how adiponectin levels were affected in acromegalic patients and 
the relationship between adiponectin levels and cardiac parameters.
Material and Methods. We included 30 subjects (15 male, 15 female), diagnosed with acromegaly and 30 healthy 
(10 male, 20  female) subjects. Serum glucose, insulin, GH, IGF-1 and adiponectin levels were obtained and the 
insulin resistance of the subjects was calculated. Echocardiographic studies of the subjects were performed.
Results. We determined that adiponectin levels were significantly higher in the acromegalic group than the con-
trol group. In the acromegalic group, there was no statistically significant relation between serum adiponectin and 
growth hormone (GH), or insulin-like growth factor-1 (IGF-1) levels (p = 0.3, p = 0.1). We demonstrated that 
cardiac function and structure are affected by acromegaly. IVST, PWT, LVMI, E/A ratio, DT, ET, IVRT, VPR, and 
LVESV values were increased and the results were statistically significant. In the acromegalic group, adiponectin 
levels were positively related with left ventricle mass index (LVMI) but this correlation was found to be statistically 
weak (p = 0.03). In our study, there was a positive correlation between VAI and LVM. We also could not find any 
correlation between VAI and adiponectin levels.
Conclusions. Although insulin resistance and high insulin levels occur in active acromegaly patients, adiponectin 
levels were higher in our study as a consequence of GH lowering therapies. Our study showed that adiponectin lev-
els may be an indicator of the cardiac involvement acromegaly. However, the usage of serum adiponectin levels in 
acromegalic patients as an indicator of cardiac involvement should be supported with other, wide, multi-centered 
studies (Adv Clin Exp Med 2016, 25, 3, 449–455).
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fluence cardiac remodeling [11, 12]. Low levels of 
adiponectin are associated with a further progres-
sion of left ventricular hypertrophy in patients pre-
senting with hypertension, left ventricular diastol-
ic dysfunction, and hypertrophy [13]. Adiponectin 
may serve to limit pathological cardiac remodel-
ing, which leads to hypertrophy and diastolic dys-
function. Serum adiponectin levels are paradoxi-
cally higher in patients with chronic heart failure; 
they were an independent predictor of mortal-
ity  [14, 15]. Adiponectin may play a  role in the 
mechanism of heart failure. However, the effect of 
adiponectin seems to differ under different condi-
tions and in different study populations.
Cardiovascular disorders are the leading 
causes of morbidity and mortality in patients with 
acromegaly  [7, 8]. The  growth hormone/insulin-
like growth factor-1 (GH/IGF-1) axis has a direct 
endocrine effect on the myocardium, resulting in 
hypertrophy, enhancement of contractile perfor-
mance, and elongation of the action potential of 
cardiac fibers  [9]. Acromegaly involves complex 
mechanisms that interfere with the function of the 
heart, including coronary ischemia, chronic heart 
failure, and valvular disease.
Because acromegaly is also a  systemic disor-
der characterized by morbidities similar to those 
of a  metabolic syndrome, hypoadiponectinemia 
may be involved in the pathogenesis of insulin re-
sistance and related metabolic disorders as well 
as cardiac changes present in active acromega-
ly  [10–17]. Indeed, adiponectin levels in acrome-
galic patients have been reported variably as higher 
than [18] or similar to [19, 20] those in normal con-
trols. The effect of GH-reducing therapy on serum 
adiponectin levels has also been studied  [21,  22]. 
The  relationship between adiponectin levels and 
cardiac parameters has not been studied.
The aim of this study was to find out how ad-
iponectin levels were affected in subjects with ac-
tive and inactive acromegaly and any relationship 
between adiponectin levels and cardiac parameters 
in acromegalic patients.
Material and Methods
The  study protocol conformed to the ethical 
guidelines of the Declaration of Helsinki as reflect-
ed in a prior approval by the institution’s human 
research committee. The  study was approved by 
the Ethics Committee of Pamukkale University.
Patient Characteristics
Thirty patients (15 male, 15 female) who were 
diagnosed with acromegaly and 30 healthy control 
subjects (10 male, 20 female) were included in the 
study. The subjects in both study groups were be-
tween 35 and 60 years old and both groups were 
similar with respect to mean age. Twenty-five pa-
tients were diagnosed with hypophyseal macroad-
enoma, and the remaining subjects were diagnosed 
with microadenoma during the first visit. Patients 
with nadir GH ≤ 1 μg/L after OGTT (oral glucose 
tolerance test) and normal IGF-1 levels accord-
ing to age and sex were classified as inactive, and 
patients with nadir GH > 1 μg/L after OGTT and 
higher IGF-1 levels were classified as having active 
acromegaly. Three months before the evaluation, 
the patients stopped insulin-sensitizing treatment 
to avoid any interference with the analyzed met-
abolic parameters. Blood samples were collected 
and a  cardiac analysis was performed before any 
treatment for this study. (All subjects in the patient 
group were treated with somatostatin analogs, and 
22 subjects were also treated with surgery; 7 were 
treated with a combination of both surgery and ra-
diotherapy). Twenty-three subjects with insulin 
resistance received insulin sensitizing therapy with 
either glitazones or metformin.
All of the healthy subjects had a normal body 
mass index (BMI), fasting plasma glucose levels 
(FPG), and IR parameters. None of the healthy sub-
jects had drug usage or cardiac disease demonstrated 
with history, electrocardiography or echocardiog-
raphy. None of the acromegalic group and control 
group had been diagnosed with hypertension. An-
thropometric measurements (weight, height, waist 
circumference) of the subjects were obtained as they 
were in a prone position after 8 hours fasting.
Laboratory Methods
After 10 min of resting, arterial blood pressures 
were obtained with an aneroid sphygmomanome-
ter. Blood samples for glucose, insulin, GH, IGF-1, 
and adiponectin were obtained after 8 h of fasting. 
Serum insulin levels of the subjects were ana-
lyzed by an Architect autoanalyzer using a  com-
mercially available, solid phase chemilumines-
cence immunometric procedure (Abbott, USA). 
Insulin resistance was calculated according to the 
HOMA  method as follows: {[glucose(mg/dL)/18] 
X  insulin (μU/mL)}/22.5  [23]. A  HOMA-IR val-
ue above 2.7 was considered to show insulin resis-
tance. Serum adiponectin, IGF-1 and GH concen-
trations were determined using ELISA kits.
The visceral adiposity index (VAI) was calcu-
lated as described [19], using the following formu-
las, differentiated according to sex, where triglyc-
eride (TG) levels are expressed in millimoles per 
liter and HDL-cholesterol levels expressed in mil-
limoles per liter:
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for males, VAI: [WC/39.68 + (1.88 × (BMI)] × 
× (TG/1.03) × (1.31/HDL);
for females, VAI: [WC/36.58 + (1.89 × BMI)] × 
× (TG/0.81) × (1.52/HDL).
According to the specific, age-stratified cutoff 
points of VAI identifying patients with presumed 
visceral adipose dysfunction and cardiometabolic 
risk [24], we divided the patients into two groups: 
those with normal VAI (group A) and those with 
high VAI (group B)
M-mode, two-dimensional, and pulsed Dop-
pler echocardiographic studies were performed 
with a  commercial ultrasound system, Vivid 7, 
using a  2.5-MHz transducer during three to five 
consecutive cardiac cycles. The  following mea-
surements were recorded on an M-mode trace: left 
atrium diameter, left ventricular end-diastolic vol-
ume (LVEDV), left ventricular end-systolic vol-
ume (LVESV), interventricular septum thickness 
(IVST), left ventricular posterior wall thickness 
(PWT), left ventricular ejection fraction (LVEF), 
and fractional shortening. Left ventricle mass 
(LVM) was calculated with the Devereux Formula. 
We calculated LVM index by dividing LVM by the 
body surface area. The  myocardial performance 
index (MPI) indicator of cardiac function is de-
fined as the sum of isovolumetric contraction time 
(ICT) and isovolumetric relaxation time (IVRT) 
divided by ejection time (ET).
Statistical Analysis
The SPSS program (Statistical Package for So-
cial Sciences, v. 11.0 for Windows) was used for 
statistical analysis and the results were expressed 
as mean  ±  standard deviation. Two-tailed 95% 
confidence intervals and p values were given, with 
p  <  0.05 regarded as significant. In  the statistical 
evaluations, 1-way analysis of variance test was 
used to observe any differences between the control 
group, active acromegaly and inactive acromegal-
ic patient groups relating to blood values and car-
diac parameters. In the determination of different 
groups, the Duncan multiple comparison meth-
od was used. In addition, Spearman Rank Corre-
lation Coefficient, unpaired t-tests were used. Ad-
justments cannot be done because assumptions of 
multivariate normality are not achieved due to the 
small sample size.
Results
In this study, statistically significant differenc-
es were observed in fasting plasma glucose, insu-
lin, HOMA-IR, growth hormone and adiponectin 
levels between the active and passive acromegal-
ic groups. The clinical and biochemical findings of 
patients and controls are shown in Table 1. Adi-
ponectin levels were higher in acromegalics than 
in the controls and this difference was statistical-
ly significant. Adiponectin levels did not correlate 
with GH and IGF-1 levels.
Among the patients, the mean VAI value 
was 1.8  ±  1.4. VAI directly correlated with LVM 
(R = 0.55, p = 0.034). No correlation was found re-
garding adiponectin. There was no correlation be-
tween IGF-1 and insulin. The  adiponectin levels 
were also similar in groups A and B.
Table 1. Clinical and demographic properties between groups*
Active (n = 19) Inactive (n = 11) Control (n = 30) p-value
Mean age 54.11 ± 9.99 50.80 ± 4.15 48.53 ± 9.18 ns.
BMI (kg/m²) 27.66 ± 2.00a 31.76 ± 6.44b 25.06 ± 2.78 a 0.001
SBP (mm Hg) 123.33 ± 15.81ab 130.00 ± 20.00a 115.67 ± 10.06b 0.001
DBP (mm Hg) 83.88 ± 9.93 76.00 ± 15.16 75.67 ± 7.28 ns.
FPG (mg/dL) 106.33 ± 11.41a 123.00 ± 39.54b  89.20 ± 6.26c 0.001
Insulin (µIU/mL) 5.02 ± 2.24a 9.12 ± 4.29b 6.51 ± 2.45a 0.05
HOMA-IR 1.27 ± 0.59a 2.65 ± 1.22b 1.40 ± 0.53a 0.01
GH (ng/mL) 17.79 ± 17.70a 6.90 ± 2.52b 0.68 ± 1.29b 0.001
IGF-1 (ng/mL) 634.33 ± 504.00a 569.60 ± 335.41a 124.54 ± 44.86b 0.001
Adiponectin (µg/mL) 100.59 ± 100.59a 39.23 ± 39.18ab 28.84 ± 58.72b 0.001
* The differences between the means of groups carrying different letters in the same column are statistically significant. 
BMI – body mass index; SBP – systolic blood pressure; DBP – diastolic blood pressure; FPG – fasting plasma glucose; 
HOMA-IR – homeostasis model assessment; GH – growth hormone; IGF-1 – insulin like growth factor-1.
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The  echocardiographic findings between 
groups are shown in Table 2. IVST, PWT, LVM, 
left ventricular mass index (LVMI), early transmi-
tral maximal flow velocity/atrial transmitral max-
imal flow velocity (E/A) ratio, deceleration time 
of E-wave (DT), ejection time (ET), isovolumet-
ric relaxation time (IVRT), velocity of mitral flow 
propagation (VPR), and LVESV values were sig-
nificantly greater in acromegalic patients (Table 2). 
In the acromegalic group, adiponectin levels were 
positively related (p = 0.03) (Table 3).
Discussion
The most common feature of acromegalic car-
diomyopathy is concentric biventricular hypertro-
phy [25, 26]. Cardiac valve disease is also underes-
timated: Lie and Grossman [27] found mitral and 
aortic abnormalities in 19% of their autopsy se-
ries. Colao et  al. demonstrated a  high prevalence 
of both mitral and aortic valve dysfunction in pa-
tients with active acromegaly  [28]. Cardiac valve 
abnormalities were associated with left ventricular 
hypertrophy [28, 29]. Increased stroke volume and 
cardiac output and decreased end-systolic stress 
Table 2. Echocardiographic findings obtained between groups*
Active (n = 19) Inactive (n = 11) Control (n = 30) p-value
IVST (mm) 10.11 ± 1.61a 11.00 ± 1.22a 6.93 ± 2.93b 0.001 
PWT (mm) 9.77 ± 1.98a 10.80 ± 1.48a 6.93 ± 3.03b 0.001 
LVM (g) 219.70 ± 46.78a 257.40 ± 109.08a 128.46 ± 37.13b 0.001 
LVMI (g/m²) 118.58 ± 20.82a 145.00 ± 35.99b 76.65 ± 15.08c 0.001 
E-velocity (mm/s) 0.80 ± 0.15a 0.60 ± 0.15b 0.77 ± 0.14a 0.05
A-velocity (mm/s) 0.83 ± 0.17a 0.67 ± 0.07b 0.67 ± 0.13b 0.05
E/A ratio 0.98 ± 0.29 0.92 ± 0.29 1.19 ± 0.36 ns.
DT 214.66 ± 58.45 210.00 ± 38.25 191.06 ± 32.9 ns.
ET 307.33 ± 37.07a 311.20 ± 35.84a 276.93 ± 26.72b 0.001
IVRT 112.88 ± 14.47a 110.60 ± 14.17a 97.00 ± 11.73b 0.001
VPR 56.55 ± 17.32a 56.00 ± 14.12a 45.06 ± 8.87b 0.01
MPI 0.77 ± 0.19 0.65 ± 0.38  0.66 ± 0.14 ns.
LVEDV 74.77 ± 32.88a 112.40 ± 40.25b 102.46 ± 23.86b 0.05
LVESV 34.44 ± 7.69a 46.00 ± 16.43b 31.90 ± 11.06a 0.05
EF (%) 64.55 ± 8.15 63.80 ± 8.19 64.06 ± 5.63 ns.
* The differences between the means of groups carrying different letters in the same column are statistically significant. 
ns. – non-significant. IVST – thickness of interventricular septum in diastole; PWT – thickness of left ventricular posterior 
wall in diastole; LVM – left ventricular mass; LVMI – left ventricular mass index; E – early transmitral maximal flow velo-
cities; ET – ejection time; A – atrial transmitral maximal flow velocity; IVRT – isovolumetric relaxation time; DT – decelera-
tion time of E-wave; VPR – velocity of mitral flow propagation; MPI – myocardial performance index; LVEDV – left ven-
tricle end-diastolic volume; LVESV – left ventricle end-systolic volume; EF – left ventricular ejection fraction.
Table 3. Adiponectin levels in the acromegalic group in relation to LVM, LVMI, ET, MPI, LVEDV and LVESV
LVM LVMI ET MPI LVEDV LVESV
Adiponectin (µg/mL) 0.306 0.404 –0.202 0.189 0.084 0.011
0.107 0.030* 0.285 0.316 0.659 0.399
* p-value < 0.05; statistically significant. IVST – thickness of interventricular septum in diastole; PWT – thickness of left 
ventricular posterior wall in diastole; LVM – left ventricular mass; LVMI – left ventricular mass index; E – early transmitral 
maximal flow velocities; A – atrial transmitral maximal flow velocity; IVRT – isovolumetric relaxation time; DT – decelera-
tion time of E-wave; VPR – velocity of mitral flow propagation; MPI – myocardial performance index; LVEDV – left ven-
tricle end-diastolic volume; LVESV – left ventricle end-diastolic volume; EF – left ventricular ejection fraction.
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and systemic vascular resistance were observed in 
some studies  [30, 31]. In  our study, IVST, PWT, 
LVM, LVMI, DT, ET, IVRT, VPR, and LVESV val-
ues were significantly greater in acromegalic pa-
tients showing biventricular hypertrophy and im-
pairment of diastolic and systolic function.
Several recent findings have suggested that ad-
iponectin is able to influence cardiac remodeling 
in pathologic states. Under normal circumstances, 
adiponectin would restrain the resulting hypertro-
phy. In a large group of Japanese men, adiponectin 
was inversely and independently associated with 
electrocardiographic evidence of LVH [32]. An in-
verse relationship between plasma adiponectin and 
LVM index was described in patients with type 2 
diabetes [33] and essential hypertension [13]. Hy-
poadiponectinemia or functional adiponectin re-
sistance perhaps secondary to downregulation of 
adiponectin receptors  [34] may contribute to an 
exaggerated hypertrophic response to hemody-
namic load and to inappropriate LVH [35]. In our 
study, adiponectin levels in the acromegalic group 
were found to correlate positively with LVMI 
(p = 0.03). Although we expected to find an inverse 
correlation between adiponectin levels and LVMI, 
in our study the positive correlation between adi-
ponectin levels and LVMI may have been due to 
somatostatin analog treatment.
Data regarding adiponectin levels in active ac-
romegaly available in the literature is variable as 
lower than  [22], higher than  [18] or similar to 
[19,  20] those in normal controls. The  effect of 
GH-reducing therapy on serum adiponectin lev-
els has also been studied  [21, 22]. Olarescu et  al. 
measured adipokines in 37 patients with active ac-
romegaly before and after treatment. At baseline, 
they found that total body lean mass was corre-
lated negatively with high-molecular weight ad-
iponectin (HMWAD), adiponectin and leptin. 
No significant changes were observed in the fast-
ing glucose, adiponectin and leptin levels fol-
lowing treatment. In  the transsphenoidal sur-
gery (TS) group, adiponectin, vascular endothelial 
growth factor-A  (VEGF-1), monocyte chemotac-
tic protein 1 (MCP1), and thioredoxin (TRX) de-
creased significantly. In  the somatostatin analogs 
(SA), group leptin increased, while in the pegvi-
somant (PGV) group HMWAD increased signif-
icantly  [21]. Silha et  al. found increased, rather 
than decreased, adiponectin levels in a  study in-
volving 18 patients with acromegaly compared to 
BMI- and sex-matched controls. In that study, in-
sulin resistance and fasting serum glucose were 
not significantly different between the acromegalic 
patients and control subjects, with fasting insulin 
in the patients being only 24% higher than in the 
control group [18]. In accordance with that study, 
we found the increased adiponectin levels and al-
so HOMA-IR values of patients and controls were 
similar. They stated that these results may be due 
to the small sample size, we confirmed their results 
with a larger sample size. On the other hand, Lam 
et  al. stated that the patients in their study were 
significantly more insulin resistant and had lower 
adiponectin levels, which are reversible with GH- 
-lowering therapies [22]. The discrepancies in se-
rum insulin and adiponectin levels in acromega-
ly patients may be due to the therapy that patients 
were taking for the control of GH.
GH excess also causes alterations in body com-
position, leading to reduced fat mass and increased 
lean body mass, which are reversible with treat-
ment for acromegaly. Treatment with octreotide 
(or Sandostatin) is accompanied by an increase in 
total body fat [36]. The serum adiponectin level has 
been shown to vary inversely with total body fat 
in large population-based studies  [38]. BMI does 
not distinguish between fat mass and lean body 
mass. Not measuring and monitoring the body 
fat change by bioelectrical impedance analysis is 
a  limitation of our study. To  bypass this limita-
tion, we calculated VAI. It is proposed that, based 
on simple anthropometric and metabolic param-
eters, VAI as a surrogate marker of adipose tissue 
function and distribution independently correlat-
ed with cardiometabolic risk in the general pop-
ulation. Further, acromegaly may reflect a condi-
tion of cardiometabolic risk, characterized by an 
altered production of adipocytokines, IR, and in-
adequate insulin secretion  [19]. In  our study, 
group A and group B patients had similar adipo-
nectin levels. We also could not find any correla-
tion between VAI and adiponectin levels. On the 
other hand, Ciresi et  al.  [24] found lower adipo-
nectin levels in group B and a strongly significant 
inverse correlation between VAI and adiponectin. 
In our study, there was a positive correlation be-
tween VAI and LVM. This may be an important 
way for VAI to assess cardiac risk in acromegalics.
The  authors have concluded that acromegaly 
is a systemic disorder that affects glucose tolerance, 
body composition, cardiac structure, and cardiac 
function. This study showed that adiponectin lev-
els were also affected in acromegaly. Adiponectin 
levels were three-fold higher in active acromegalic 
patients than inactive acromegalic patients. Adipo-
nectin levels may be useful for the evaluation of ac-
romegaly as well as active and inactive acromegaly.
Adiponectin levels may be an indicator of the 
cardiac involvement of acromegaly. However, the 
usage of serum adiponectin levels in acromegalic 
cardiomyopathy as an indicator of cardiac involve-
ment should be supported with other, wide, multi-
centered studies.
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